Analysis

Turnstone Biologics Corp. (NASDAQ: TSBX) Faces Challenges Despite Promising Pipeline

11/10/2024

News

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer (“SITC”) Annual Meeting.

03/28/2025

Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?

Turnstone Biologics Corp. (TSBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

02/07/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Turnstone Biologics Corp. (TSBX) a buy, sell, or hold?

Turnstone Biologics Corp. (TSBX) can hold. Click on Rating Page for detail.

What is Turnstone Biologics Corp.'s stock price?

The price of Turnstone Biologics Corp. (TSBX) is 0.35 and it was updated on 2025-04-26 01:50:36.

Is Turnstone Biologics Corp. (TSBX) overvalued or undervalued?

Currently Turnstone Biologics Corp. (TSBX) is in undervalued.

News

From:

To:

News
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D. Tue, Nov. 05, 2024
Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study Turnstone Biologics Corp. TSBX stock is trading lower after the company released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC) on Thursday. Thu, Aug. 15, 2024
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today? Turnstone Biologics (NASDAQ: TSBX ) stock is falling on Thursday following the release of the clinical-stage biotechnology company's earnings report. The bad news pulling TSBX stock down today is the company's diluted earnings per share of -92 cents. Thu, Aug. 15, 2024
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. “We have continued to bolster our position by making advances across our pipeline and corporate operations in the second quarter of 2024. Wed, Aug. 14, 2024
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year Favorable tolerability profile and demonstrated manufacturing success Product characterization and translational data support biological hypothesis for Selected TILs SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer (“MSS mCRC”). Turnstone's Phase 1 STARLING trial is an ongoing muti-site, first-in-human, non-randomized, open label, single-dose study, and is evaluating the safety, tolerability, and clinical activity of TIDAL-01. Wed, Aug. 14, 2024

SEC Filings

SEC Filings
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 04/01/2025
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 03/31/2025
Turnstone Biologics Corp. (TSBX) - 10-K - Current report SEC Filings 03/31/2025
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 02/04/2025
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 11/12/2024
Turnstone Biologics Corp. (TSBX) - 10-Q - Quarterly Report SEC Filings 11/12/2024
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 10/11/2024
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 10/01/2024
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 08/14/2024
Turnstone Biologics Corp. (TSBX) - 10-Q - Quarterly Report SEC Filings 08/14/2024
Turnstone Biologics Corp. (TSBX) - 4 SEC Filings 07/02/2024
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 06/05/2024
Turnstone Biologics Corp. (TSBX) - SC 13G/A SEC Filings 05/31/2024
Turnstone Biologics Corp. (TSBX) - S-8 SEC Filings 05/13/2024
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 05/13/2024
Turnstone Biologics Corp. (TSBX) - 10-Q - Quarterly Report SEC Filings 05/13/2024
Turnstone Biologics Corp. (TSBX) - SC 13G/A SEC Filings 04/29/2024
Turnstone Biologics Corp. (TSBX) - DEFA14A SEC Filings 04/22/2024
Turnstone Biologics Corp. (TSBX) - DEF 14A SEC Filings 04/22/2024
Turnstone Biologics Corp. (TSBX) - ARS SEC Filings 04/22/2024
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 04/16/2024
Turnstone Biologics Corp. (TSBX) - 4 SEC Filings 04/16/2024
Turnstone Biologics Corp. (TSBX) - 3 SEC Filings 04/16/2024
Turnstone Biologics Corp. (TSBX) - 10-K - Current report SEC Filings 03/22/2024
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 03/21/2024
Turnstone Biologics Corp. (TSBX) - SC 13G SEC Filings 03/18/2024
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 03/05/2024
Turnstone Biologics Corp. (TSBX) - 10-Q - Quarterly Report SEC Filings 09/01/2023
Turnstone Biologics Corp. (TSBX) - SC 13G SEC Filings 07/27/2023
Turnstone Biologics Corp. (TSBX) - S-8 SEC Filings 07/25/2023
Turnstone Biologics Corp. (TSBX) - 8-K - Current report SEC Filings 07/25/2023
Turnstone Biologics Corp. (TSBX) - SC 13D SEC Filings 07/24/2023
Turnstone Biologics Corp. (TSBX) - 424B4 SEC Filings 07/21/2023

Press Releases

StockPrice Release
Turnstone biologics corp. reports fourth quarter and full year 2024 financial results 03/28/2025
Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2024 society for immunotherapy of cancer (sitc) annual meeting 11/05/2024
Turnstone biologics corp. reports second quarter 2024 financial results and provides recent business highlights 08/14/2024
Turnstone biologics corp. reports positive initial data from phase 1 trial of tidal-01 in metastatic colorectal cancer 08/14/2024
Turnstone biologics corp. reports first quarter 2024 financial results and provides recent business highlights 05/13/2024
Turnstone biologics to present at the 2024 bank of america securities health care conference 05/08/2024
Turnstone biologics appoints william waddill to its board of directors 04/16/2024
Turnstone biologics corp. reports fourth quarter and full year 2023 financial results and provides recent business highlights 03/21/2024
Turnstone biologics to participate in upcoming investor conferences 02/21/2024
Turnstone biologics announces the passing of chief legal officer p. joseph campisi, jr., esq. 02/20/2024
Turnstone biologics to participate in the piper sandler 35th annual healthcare conference 11/27/2023
Turnstone biologics corp. reports third quarter 2023 financial results and provides recent business highlights 11/09/2023
Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) annual meeting 11/03/2023
Turnstone biologics expands scientific advisory board with appointment of dr. jeffrey s. weber 10/30/2023
Turnstone biologics to present preclinical data for selected tumor-infiltrating lymphocyte (til) therapy at society for immunotherapy of cancer's (sitc) 38th annual meeting 09/28/2023
Turnstone biologics corp. reports second quarter 2023 financial results and provides business update 09/01/2023
Turnstone biologics corp. announces pricing of upsized initial public offering 07/21/2023

More Headlines

News
4 Stocks Under $5 To Buy Now Are you looking for stocks to buy with low price tags? 08/08/2024
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. “We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies,” said Sammy Farah, M.B.A. 05/13/2024
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada. 05/08/2024
Turnstone Biologics Appoints William Waddill to its Board of Directors SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. 04/16/2024
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights. 03/21/2024
Turnstone Biologics to Participate in Upcoming Investor Conferences SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences: TD Cowen 44 th Annual Global Health Care Conference Type: Presentation and one-on-one investor meetings Speaker: Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer Date: Wednesday, March 6, 2024 Presentation Time: 2:10pm ET / 11:10am PT Location: Boston, MA Leerink Partners Global Biopharma Conference 2024 Type:Date:Location: One-on-one investor meetingsWednesday, March 13, 2024Miami, FL A live webcast of the presentation may be accessed on the Events page of Turnstone's Investor Relations website at https://ir.turnstonebio.com, where a replay will also be available for a limited period. 02/21/2024
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq. SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced with sadness that P. Joseph Campisi, Jr., Esq, the Company's Chief Legal Officer, passed away on February 1, 2024, following a prolonged battle with cancer. 02/20/2024
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference Dr. Sammy Farah, President and CEO of Turnstone, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York. 11/27/2023
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights – Promising preclinical data showcasing Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 – – Lead program, TIDAL-01, advancing and on track in two Phase 1 trials with initial clinical data expected mid-2024 – – Upsized IPO extends runway into Q2 2025 and supports advancement of pipeline through key milestones – – Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber – SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the quarter ended September 30, 2023, and provided recent business highlights. 11/09/2023
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Posters showcase Turnstone's novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors. 11/03/2023
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone's continued advancement of its Selected TIL therapies 10/30/2023
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced four posters reporting preclinical data for Turnstone's Selected TIL therapies will be presented at the 38 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). 09/28/2023
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent business highlights. 09/01/2023
FMR LLC Acquires Significant Stake in Turnstone Biologics Corp On July 25, 2023, FMR LLC (Trades, Portfolio), a renowned investment firm, made a significant move in the biotechnology sector by acquiring a substantial stake in Turnstone Biologics Corp ( TSBX , Financial). This article provides an in-depth analysis of the transaction, profiles of both FMR LLC (Trades, Portfolio) and Turnstone Biologics Corp, and the potential implications of this acquisition on the market. 07/27/2023
Turnstone Biologics set to go public as upsized $80 million IPO pricing at low end of expected range Turnstone Biologics Corp. TSBX, is headed for its public debut Friday, as the San Diego-based biotechnology company focused on treating tumors raised $80 million through an upsized initial public offering. The company said it sold 6.67 million shares in the IPO, up from a previously expected offering of 5.80 million shares. 07/21/2023
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced the pricing of its upsized initial public offering of 6,666,667 shares of common stock at a price to the public of $12.00 per share. All shares of common stock are being offered by Turnstone. The gross proceeds to Turnstone from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Turnstone, are expected to be $80.0 million. In addition, Turnstone has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. 07/21/2023
IPO Update: Turnstone Biologics Readies $75 Million IPO Plan Turnstone Biologics Corp. has filed proposed terms for a $75.4 million IPO. The firm is developing drug treatment candidates for solid tumors and other cancer conditions. Turnstone Biologics' major partners have terminated their collaboration agreements, so I'm cautious about the firm's prospects. 07/17/2023
Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each Turnstone Biologics TSBX, , a clinical-stage biotech that specializes in treatments for solid tumors, set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $12 to $14 each. The company would raise $81.2 million at the top of that range at a valuation of $298 million. 07/17/2023

Unlock

TSBX Ratings Summary

TSBX Quant Ranking

Is Turnstone Biologics Corp. (TSBX) a buy, sell, or hold?

What is Turnstone Biologics Corp.'s stock price?

Is Turnstone Biologics Corp. (TSBX) overvalued or undervalued?

4 Stocks Under $5 To Buy Now

Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference

Turnstone Biologics Appoints William Waddill to its Board of Directors

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Turnstone Biologics to Participate in Upcoming Investor Conferences

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber

Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

FMR LLC Acquires Significant Stake in Turnstone Biologics Corp

Turnstone Biologics set to go public as upsized $80 million IPO pricing at low end of expected range

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

IPO Update: Turnstone Biologics Readies $75 Million IPO Plan

Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt